Glenmark Pharmaceuticals Ltd 29 Apr 2024 12:00 AM
Glenmark receives USFDA approval for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC),
Glenmark Pharmaceuticals has received final approval by the United States Food & Drug Administration (U.S. FDA) for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC), determined by the FDA to be bioequivalent1 to Advil�2 Dual Action with Acetaminophen Tablets, 250 mg/125 mg (OTC), of Haleon US Holdings, LLC. Glenmark`s Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC), will be distributed in the U.S. by Glenmark Therapeutics Inc., USA. According to Nielsen� syndicated data for the latest 52 weeks period ending 23 March 2024, the Advil� Dual Action with Acetaminophen Tablets, 250 mg/125 mg (OTC) market achieved annual sales of approximately $84.1 million*.Powered by Capital Market - Live News
Glenmark Pharmaceuticals Ltd 01 Apr 2024 12:00 AM
Glenmark Pharmaceuticals directors resign,
Glenmark Pharmaceuticals announced that Sridhar Gorthi (DIN: 00035824), Devendra Raj Mehta (DIN: 01067895), Brian Tempest (DIN: 00101235) and Bernard Munos (DIN: 05198283) have retired as Independent Directors of the Company from end of the day on 31 March 2024, consequent to the completion of their second term of office as Independent Directors. Powered by Capital Market - Live News
Glenmark Pharmaceuticals Ltd 15 Feb 2024 12:00 AM
Glenmark Pharmaceuticals reports consolidated net loss of Rs 351.37 crore in the December 2023 quarter,
Net loss of Glenmark Pharmaceuticals reported to Rs 351.37 crore in the quarter ended December 2023 as against net profit of Rs 272.58 crore during the previous quarter ended December 2022. Sales declined 19.67% to Rs 2460.29 crore in the quarter ended December 2023 as against Rs 3062.75 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales2460.293062.75 -20 OPM %-8.4815.48 - PBDT-297.58447.49 PL PBT-444.66295.98 PL NP-351.37272.58 PL Powered by Capital Market - Live News
Glenmark Pharmaceuticals Ltd 13 Feb 2024 12:00 AM
Glenmark Pharmaceuticals allots 20,000 equity shares under ESOS,
Glenmark Pharmaceuticals has allotted 20,000 equity shares under ESOS on 13 February 2024. Consequent to the aforesaid allotment, the paid-up share capital of the Company has increased to 28,21,88,156 equity shares of Re. 1 each aggregating to Rs. 28,21,88,156. Powered by Capital Market - Live News
Glenmark Pharmaceuticals Ltd 01 Feb 2024 12:00 AM
Glenmark Pharmaceuticals announces board meeting date,
Glenmark Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 February 2024.Powered by Capital Market - Live News
Subscribe for our
newsletter
Open Account Now